title: Quantification of residual virulence of the Vnukovo-32/107 rabies virus vaccination strain.
abstract: The present work summarizes the results of 11 groups of experiments carried out with the aim to complexly quantify the residual virulence of a cold mutant of the Vnukovo-32/107 rabies virus vaccination strain intended for the preparation of an oral rabies vaccine (Kamark) for the immunization of free-living carnivores. According to WHO prescriptions, residual virulence was quantified in experiments on carnivores, mainly red foxes (Vulpes vulpes)--the presumed target species, and farm-bred polar foxes (Alopex lagopus)--a related species. Further experiments were carried out in cats, dogs, non-target autochthonous micromammals, predatory birds (Microtus arvalis, Apodemus flavicollis, Falco tinnunculus) and in a large number of laboratory animals--white mice. At oral administration (including extremely high doses) the strain Vnukovo-32/107 proved to be apathogenic to the target carnivores--Vulpes vulpe and Alopex lagopus as well as cats, dogs and the autochthonous micromammals. For Falco tinnunculus the strain proved to be apathogenic even at intramuscular and intracerebral administration. The residual virulence of the Vnukovo-32/107 vaccination strain, also quantified by comprehensive model experiments on white mice of different weight categories that had been infected orally, subcutaneously, intramuscularly, intracerebrally, by contact, with ingestion of rabic material or by modelled immune suppression, proved to be extremely low-levelled. The strain under investigation revealed a high level of attenuation and a low level of residual virulence and proved to be suitable for the preparation of non-reactogenic oral vaccine intended for foxes, an extremely susceptible target species.
authors.affiliation: Rabiological Laboratory, University of Veterinary Medicine, Kosice, Slovak Republic.
authors.forename: S
authors.initials: S
authors.lastname: Svrcek
authors.forename: R
authors.initials: R
authors.lastname: Ondrejka
authors.forename: Z
authors.initials: Z
authors.lastname: Benísek
authors.forename: O J
authors.initials: OJ
authors.lastname: Vrtiak
authors.forename: M A
authors.initials: MA
authors.lastname: Selimov
authors.forename: J
authors.initials: J
authors.lastname: Závadová
authors.forename: A
authors.initials: A
authors.lastname: Durove
authors.forename: J
authors.initials: J
authors.lastname: Süliová
authors.forename: M
authors.initials: M
authors.lastname: Mad'ar
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002371:Cat Diseases / Q000517:prevention & control; D002415:Cats; D004283:Dog Diseases / Q000517:prevention & control; D004285:Dogs; D005589:Foxes; D051379:Mice; D011818:Rabies / Q000517:prevention & control / Q000662:veterinary*; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D011820:Rabies virus / Q000472:pathogenicity; D014774:Virulence
chemical_list: D011819:Rabies Vaccines